MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ
0.5992
-0.0490
-7.56%
After Hours: 0.5800 -0.0192 -3.20% 17:32 03/12 EDT
OPEN
0.6288
PREV CLOSE
0.6482
HIGH
0.6288
LOW
0.5400
VOLUME
786.72K
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
0.5400
MARKET CAP
54.99M
P/E (TTM)
-0.3280
1D
5D
1M
3M
1Y
5Y
1D
Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines
NASDAQ · 23h ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
Verrica Pharmaceuticals filed $150M mixed securities shelf
Seeking Alpha · 1d ago
Verrica Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 1d ago
VERRICA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $150 MLN - SEC FILING
Reuters · 1d ago
Verrica Pharmaceuticals GAAP EPS of -$0.24 beats by $0.01, revenue of $0.34M misses by $0.96M
Seeking Alpha · 1d ago
Verrica Pharmaceuticals Q4 2024 Adj. EPS $(0.18) Beats $(0.26) Estimate, Sales $344.000K Miss $1.041M Estimate
Benzinga · 1d ago
*Verrica Pharmaceuticals 4Q Rev $344,000 >VRCA
Dow Jones · 1d ago
More
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Webull offers Verrica Pharmaceuticals Inc stock information, including NASDAQ: VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.